ZenasZenas raises $200m to advance autoimmune antibody therapy
Phase 2Breakthrough TherapyPhase 3Gene TherapyPhase 1
Preview
Source: Pharmaceutical Technology
Zenas, which has recently raised $200m, is evaluating obexelimab in multiple autoimmune disorders, including IgG4-related disease, systemic lupus erythematosus, and more. Credit: Dilok Klaisataporn / Shutterstock.
US-based Zenas BioPharma has raised $200m in a Series C round to support the clinical development of its lead candidate, obexelimab.
The investors included multiple US-based venture capital companies such as SR One, New Enterprise Associates (NEA), Norwest Venture Partners, Delos Capital, and others. The Series C funds will go towards supporting the “mid to late stage” clinical development programmes of obexelimab, a bispecific antibody that targets CD19 and FcγRIIb. Zenas acquired the rights to the antibody from Xencor in 2021.
In September 2023, Bristol Myers Squibb (BMS) acquired the developmental and marketing rights to obexelimab in several Asia Pacific regions, including Australia, Hong Kong, Japan, Singapore, South Korea and Taiwan. BMS made an equity investment in and paid $50m upfront to ZenasZenas, which is also eligible for additional milestone-based payments.
Zenas is evaluating obexelimab in a placebo-controlled Phase III INDIGO trial (NCT05662241) as a subcutaneous treatment for IgG4-related disease (IgG4-RD), a chronic fibroinflammatory disease. The study is expected to enrol approximately 200 participants with IgG4-RD.
An open-label Phase II/III SApHiAre trial (NCT05786573) is also evaluating obexelimab as a treatment for warm autoimmune haemolytic anaemia (wAIHA). Both the IgG4-RD and wAIHA trials are expected to conclude in late 2025 or early 2026.
Preview
Source: Pharmaceutical Technology
FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy
Preview
Source: Pharmaceutical Technology
Zenas also plans to start Phase II trials investigating the bifunctional antibody as a treatment for multiple sclerosis and systemic lupus erythematosus (SLE), for which obexelimab has previously shown mixed results as a treatment. In 2018, it failed to meet the primary endpoint of maintenance of improvement in SLE in a Phase II trial (NCT02725515). Additionally, the Xencor-sponsored trial did meet the secondary endpoint, with treated patients taking a median of 76% longer to show losses in improvement.
The current Series C funds add to the $118m in a Series B round that Zenas raised in 2022. Other autoimmune candidates in the company’s portfolio include ZB002, an anti-TNFα therapy, and ZB004, a cytotoxic T lymphocyte-associated antigen-4 immunoglobulin (CTLA-4-Ig) fusion protein. The two therapies were also acquired from Xencor.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.